Open AccessThe BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders
Author(s) -
Robert Aude,
Pujals Anaïs,
Favre Loetitia,
Debernardi Justine,
Wiels Joëlle
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12759
Subject(s) - rituximab , lymphoproliferative disorders , lymphoma , cancer research , medicine , epstein–barr virus , apoptosis , b cell lymphoma , immunology , cyclophosphamide , chemotherapy , virus , biology , biochemistry
Tumor cells infected by Epstein–Barr virus (EBV) express latency proteins, among which LMP1 is able to increase the level of the anti‐apoptotic protein BCL‐2, today considered as an attractive target for therapeutic strategies. Our results suggest that agents targeting BCL‐2, used either alone or in combination with rituximab, represent a novel promising approach for post‐transplant EBV‐positive B lymphoproliferative disorder treatment.